Exelixis Inc at BMO Capital Markets Prescription for Success Healthcare Conference Transcript
Wonderful. Good morning. Thanks for -- to all of you for being here. My name is George Farmer, Senior Biotech Analyst with BMO Capital Market. With me today -- I'll first kickoff fireside chat with the management team from Exelixis, a company that I personally have been following for quite some time, has been through a lot of changes and has a very interesting drug on the market for treating renal cell carcinoma and hepatocellular carcinoma as well as an interesting science behind the company.
With me today is Chris Senner, the CFO of Exelixis; and Andrew Peters, VP of Strategy. And we're going to just talk about the company for a little bit. Why don't we get started? Perhaps you guys can provide a high-level view of Exelixis' business model and going through some general aspects about the pipeline?
Sure. So first of all, George, thanks for having us here. Before I get started, we'll be making forward-looking statements. So I'll
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
